The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Oscar Bobo for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Bobo engaged in a pattern of importing or offering for import misbranded drugs (i.e., in an amount, frequency, or dosage that is inconsistent with his personal or household use) that are not designated in an authorized electronic data interchange system as products regulated by FDA. Mr. Bobo was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 25, 2026 (30 days after receipt of the notice), Mr. Bobo had not responded. Mr. Bobo's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Abstract as published in the Federal Register.
The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.
View on federalregister.gov →Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.